Combination of ground-breaking treatments offer powerful new path for blood cancer therapies

(Monash University) Researchers at Monash University and Peter MacCallum Cancer Centre have identified for the first time how a new class of epigenetic drug engages with the immune system to kill off cancer cells, offering powerful new pathways for enhanced blood cancer therapies.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

Publication date: Available online 18 February 2019Source: Pharmacology &TherapeuticsAuthor(s): Alexander W. Hird, Adriana E. TronAbstractDysregulation of the mitochondrial apoptotic pathway controlled by members of the Bcl-2 protein family plays a central role in cancer development and resistance to conventional cytotoxic as well as targeted therapies. Hence, selective inhibition of pro-survival Bcl-2 family of proteins to activate apoptosis in malignant cells represents an exciting anti-cancer strategy. The remarkable clinical performance of the selective Bcl-2 antagonist venetoclax has highlighted the potential for ...
Source: Pharmacology and Therapeutics - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 18 February 2019Source: Pharmacology &TherapeuticsAuthor(s): Viviana I. Torres, Juan A. Godoy, Nibaldo C. InestrosaAbstractCommunication between cells occurs through secreted molecules, among which Wnt ligands play a critical role in balancing cell proliferation, differentiation and cellular homeostasis. The action of Wnt signaling can be modulated at several levels, including posttranslational modification of the Wnt ligands, whose acylation is critical for biological activity. At least three enzymes are necessary for Wnt acylation/deacylation: stearoyl CoA desaturase (SCD), porcupin...
Source: Pharmacology and Therapeutics - Category: Drugs & Pharmacology Source Type: research
Clinical trials for cancer patients give the opportunity for people to try the newest cancer therapies and receive exceptional care. So why do only 8% of cancer patients enroll in one?
Source: Healthcare News - Category: Pharmaceuticals Authors: Source Type: news
Gastric acid suppressants may reduce absorption of oral cancer drugs, as shown in a study with pazopanib for sarcoma in which the interaction led to worse outcomes. Can this be practice changing?Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Here are some of the latest health and medical news developments, compiled by the editors of HealthDay: Immunotherapies Prove Their Mettle Against Kidney Cancer Adding immunotherapy to targeted cancer therapy boosted survival for kidney cancer...
Source: - Daily MedNews - Category: General Medicine Source Type: news
A shorter radiotherapy protocol for treating prostate cancer is comparable...Read more on AuntMinnie.comRelated Reading: ASTRO: AI's rad therapy future is in predicting outcomes ASTRO: SBRT works well for less risky prostate cancer ASTRO releases new prostate radiation therapy guideline SNMMI: Early prostate cancer therapy extends lives Hypofractionated RT works for prostate cancer
Source: Headlines - Category: Radiology Source Type: news
by Masayuki Maeda, Hideaki Yamashita The presence of treatment-resistant cells is an important factor that limits the efficacy of cancer therapy, and the prospect of resistance is considered the major cause of the treatment strategy. Several recent studies have employed mathematical models to elucidate the dynamics of generating resi stant cancer cells and attempted to predict the probability of emerging resistant cells. The purpose of this paper is to present numerical approach to compute the number of resistant cells and the emerging probability of resistance. Stochastic model was designed and developed a method to appr...
Source: PLoS Computational Biology - Category: Biology Authors: Source Type: research
Therapeutic implications of germline genetic findings in cancer, Published online: 19 February 2019; doi:10.1038/s41571-019-0179-3The majority of genetically targeted approaches to cancer therapy focus on somatic mutations. However, evidence is accumulating in support of a role for germline genetic alterations in determining responsiveness to treatment. In this Review, the authors summarize the therapeutic potential of knowledge of the germline genome in patients with cancer.
Source: Nature Reviews Clinical Oncology - Category: Cancer & Oncology Authors: Source Type: research
Bahulayan Kunnumakkara : The FBXW7 (F-box with 7 tandem WD40) protein encoded by the gene FBXW7 is one of the crucial components of ubiquitin ligase called Skp1-Cullin1-F-box (SCF) complex that aids in the degradation of many oncoproteins via the ubiquitin-proteasome system (UPS) thus regulating cellular growth. FBXW7 is considered as a potent tumor suppressor as most of its target substrates can function as potential growth promoters, including c-Myc, Notch, cyclin E, c-JUN, and KLF5. Its regulators include p53, C/EBP-δ, Numb, microRNAs, Pin 1, Hes-5, BMI1, Ebp2. Mounting evidence has indicated the involvement ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Electrochemical methods are powerful in the characterization and design of redox-modulating agents. We, herein, report the electrochemical investigation, in aprotic medium, of eleven synthetic 3-thio-substituted-nor-beta-lapachones, along with the determination of cytotoxic activity and correspondent selectivity index, against several cancer cell lines and one normal cell. Four of the quinones are novel compounds. The redox behavior is representative of two independent systems: the easy reduction of the quinone moiety and, at far more negative potential, the reductive cleavage of the C-S-C bonding; and the anodic part cont...
Source: Journal of the Brazilian Chemical Society - Category: Chemistry Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy